Tiny Biotech With Three Cancer Drugs Is More Alluring Takeover Bet Now
The drug is one of Spectrum’s two drugs undergoing phase 3 clinical trials. Allergan paid Spectrum $41.5 million and will make additional payments of up to $304 million based on achieving certain milestones. So far, Raj Shrotriya, Spectrum’s chairman, …
In 2007 preliminary results were released from the Phase II clinical trial of intravenous belinostat in combination with carboplatin and paclitaxel for relapsedovarian cancer. Final results in late 2009 of a phase II trial for T cell lymphomawere encouraging. Belinostat has been granted orphan drug and fast trackdesignation by the FDA.
- Plumb, Jane…
View original post 117 more words